

Supplementary Material

Article Title: Pimavanserin 34 mg at Bedtime for the Treatment of Insomnia in 6 Veterans With Posttraumatic Stress Disorder

Authors: Melissa B. Jones, MD; Ritwick Agrawal, MD; Amir Sharafkhaneh, MD, PhD; Gursimrat Bhatti, MBBS; Ruosha Li, PhD; Laura Marsh, MD; and Ricardo E. Jorge, MD


DOI Number: 10.4088/JCP.23br14992

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

1. [Figure 1](#) Change in Subjective and Objective Measures Pre- and Post-Treatment With Pimavanserin 34 mg at Bedtime for 6 Weeks (n=6)

DISCLAIMER

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.



Supplementary Figure 1. Change in subjective and objective measures pre- and post-treatment with pimavanserin 34mg at bedtime for 6 weeks (n=6). Columns and error bars correspond to mean and standard deviations, respectively. ISI=Insomnia Severity Index, PCL-5=Post-traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, PHQ-9 = Patient Health Questionnaire, PSQI (-meds)=Pittsburgh Sleep Quality Index (– use of medications), pTST=polysomnography total sleep time, hr=hour, pSOL=polysomnography sleep onset latency, pWASO=polysomnography wake after sleep onset, min=minutes, pN3=polysomnography N3 duration, aTSTavg=actigraphy average total sleep time, aSOL=actigraphy sleep onset latency, aWASOavg=actigraphy average wake after sleep onset. †n=5 (missing 1 post-treatment polysomnogram due to pandemic).